Bill Gates Pumps $40 Million into Plans to Test mRNA ‘Vaccines’ on Africans
Microsoft co-founder Bill Gates is expanding his plans to test mRNA “vaccines” on the people of Africa.
The Bill & Melinda Gates Foundation has announced a $40 million initiative to support the production of messenger RNA (mRNA) vaccines in Africa.
The globalist organization claims this investment aims to address “vaccine inequities” exposed during the COVID-19 pandemic.
During the pandemic, African nations were often the last to receive “vaccines.”
However, Gates and his foundation hope to expand the testing of the “vaccines” on Africans before they are rolled out globally.
The funding will aid several manufacturers, including Senegal’s Institut Pasteur, in developing mRNA “vaccines” for both local and global diseases.
Although the first injections may not be approved for at least three years, Bill Gates emphasized the potential of mRNA technology to combat diseases like Rift Valley fever and tuberculosis while building Africa’s capacity for vaccine development.
However, several critical factors were not addressed in the recent Institute Pasteur news release.
Assuming the “vaccines” bring quality efficacy and safety, given they are years from approval, will this investment address urgent health challenges, or is it too focused on long-term goals?
Beyond initial funding, how will African facilities ensure long-term financial and operational viability?
Will this initiative truly prioritize African needs, or could it become another example of external influence shaping local health priorities?
It raises questions about the African experience during the COVID-19 pandemic.
Why are public health authorities not raising the quandary that generally sub-Saharan populations fared better than European, American, and Asian populations during the pandemic?
This is despite the fact that vaccination rates were quite low.
The present mRNA vaccines or COVID-19 continue to exhibit severe safety issues.
However, the risks associated with these injections are not fully recognized by public health authorities.
The shots have been proven to be ineffective at stopping transmission and linked to the mutation of the virus.
The announcement highlights the Gates Foundation’s role as a benefactor, potentially overshadowing African-led efforts and raising questions about the balance of power in global health initiatives.
However, the heavy emphasis on mRNA technology might neglect other healthcare strategies that could be more immediately impactful for African diseases.
This initiative, while framed as a promising step toward addressing vaccine disparities, on the other hand, raises critical questions.
Over time, financing structures that don’t embrace local autonomy and African priorities first and foremost will likely not be sustained in today’s economic and socio-political climate.
